Nicotinic agonist and antioxidant compounds for the treatment of neurodegenerative diseases
ES2781377A1
COMPOUNDS DERIVED FROM 2-IODO-7 - (((2- (5-METOXY-1H-INDOL-3-IL) ETHYL) AMINO) METHYL) -1-ALKYL / ARYL-6,7,7A, 8-TETRAHYDRO- 3H-PIRROLO [2,1-J] QUINOLINE-3,9 (5H) -DIONA AS ANTIOXIDANT AGENTS, NRF2 INDUCERS AND NICOTINE MODULATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
ES2774407A1
MULTIVARIANT ANALYSIS METHOD IN ELECTROENCEPHALOGRAPHY (EEG) (Machine-translation by Google Translate, not legally binding)
ES2733746A2
METHOD AND NEUROPHYSIOLOGICAL APPARATUS OF IDENTIFICATION OF THE CEREBRAL NUCLEUS
ES2708900A1
NEW GRAMINE DERIVATIVES WITH PROTECTIVE EFFECT OF PHOSPHATASE ACTIVITY, AND ITS APPLICATION IN THE TREATMENT OF HUMAN DISEASES (Machine-translation by Google Translate, not legally binding)
ES2696904A1
NON INVASIVE METHOD FOR DETERMINING INTRACRANIAL PRESSURE THROUGH THE BIOELECTRIC ACTIVITY OF THE BRAIN
US2019046123A1
Method for determining the degree of activation of the trigeminovascular system
ES2670449A1
MANDIBULAR DISTRACTOR
ES2659828A2
Use of 4H-pyrano [2,3-c] pyrazole derivatives in the treatment of neurodegenerative diseases
US2018105492A1
Compounds derived from 3-alkylamine-1h-indolyl acrylate and their use in the treatment of neurodegenerative diseases
Use of the compounds derived from 3-alkyl-4-aryl-1,4,6,7,8,9-hexahydropyrazolo [4 ', 3': 5.6] pyran [2,3-b] quinolin-5- amine as dual inhibitors of GSK3B - AChE and Nrf2 inducers for the treatment of neurodegenerative diseases
